ADJUVANT CHEMOTHERAPY FOR OSTEOSARCOMA - A RANDOMIZED PROSPECTIVE TRIAL
ADJUVANT CHEMOTHERAPY FOR OSTEOSARCOMA - A RANDOMIZED PROSPECTIVE TRIAL
复制标题
DOI：
10.1200/jco.1987.5.1.21
复制
发表时间：
1987-01-01
影响因子：
45.3
通讯作者：
GOODNIGHT, J
中科院分区：
文献类型：
--
作者：
EILBER, F;GIULIANO, A;GOODNIGHT, J
为了确定化疗在骨肉瘤患者多学科治疗中的作用，1981年开始了一项术后辅助化疗的随机前瞻性试验。59名非转移性经典髓内骨肉瘤患者被随机分组； 32 名患者接受了术后辅助化疗，包括大剂量甲氨蝶呤、阿霉素（俄亥俄州哥伦布市 Adria Laboratories）和 BCD（博莱霉素、环磷酰胺、放线菌素 D），27 名患者未接受辅助化疗。在中位随访 2 年时，接受辅助化疗的患者的无病生存率和总生存率都有统计学上的显着改善。此外，与同时未接受化疗的对照相比，20世纪70年代接受治疗但未接受化疗的患者的无病生存率或总生存率<20%没有差异。因此，通过相同的分期程序、统一的手术管理和标准的病理评估，术后辅助化疗肯定会提高骨肉瘤患者的无病生存率和总生存率。
To determine the role of chemotherapy in the multidisciplinary treatment of patients with osteosarcoma, a randomized prospective trial of postoperative adjuvant chemotherapy was begun in 1981. Fifty-nine patients with nonmetastatic classic intramedullary osteosarcoma were randomized; 32 received postoperative adjuvant chemotherapy consisting of high-dose methotrexate, Adriamycin (Adria Laboratories, Columbus, OH), and BCD (bleomycin, cytoxan, actinomycin D), and 27 patients received no adjuvant chemotherapy. At a median follow-up of 2 years, there was a statistically significant improvement in both disease-free and overall survival in those who received adjuvant chemotherapy. In addition, there was no difference in the < 20% disease-free or overall survival of patients treated in the 1970s who did not receive chemotherapy, as compared with the concurrent nontreatment controls. Therefore, with identical staging procedures, uniform surgical management, and standard pathologic evaluation, postoperative adjuvant chemotherapy definitely improves disease-free and overall survival in patients with osteosarcoma.